Head and Neck Cancers Patients Clinical Trial
Official title:
Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication
The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.
| Status | Recruiting |
| Enrollment | 60 |
| Est. completion date | December 30, 2018 |
| Est. primary completion date | December 30, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: - Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department. Exclusion Criteria: - Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department. |
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | National Taiwan University Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| National Taiwan University Hospital |
Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Disease progression | Tumor local recurrence or distant metastasis | Three years |